In vitro characterization of potential CYP- and UGT-derived metabolites of the psychoactive drug 25B-NBOMe using LC-high resolution MS.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Drug Testing and Analysis

• Publication date

  2016-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/dta.1865PMID 26382567
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes.

  2015cited by this paper
• Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry.

  2015cited by this paper
• Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue.

  2015cited by this paper
• Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethyl-cathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS(n) standard screening approaches.

  2015cited by this paper
• Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MSn, and LC-HR-MS/MS

  2015cited by this paper
• Emerging drugs of abuse.

  2014cited by this paper
• Metabolism of aildenafil in vivo in rats and in vitro in mouse, rat, dog, and human liver microsomes.

  2014cited by this paper
• Emerging drugs of abuse.

  2014cited by this paper
• Determination of 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (25B-NBOMe) in serum and urine by high performance liquid chromatography with tandem mass spectrometry in a case of severe intoxication.

  2014cited by this paper
• An investigation of the stability of emerging new psychoactive substances.

  2014cited by this paper
• Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe

  2014cited by this paper
• The new drug phenomenon.

  2014cited by this paper
• LC-MS metabolic study on quercetin and taxifolin galloyl esters using human hepatocytes as toxicity and biotransformation in vitro cell model.

  2013cited by this paper
• 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): Clinical Case with Unique Confirmatory Testing

  2013cited by this paper
• The NBOMe series: a novel, dangerous group of hallucinogenic drugs.

  2013cited by this paper
• In vitro metabolism studies on mephedrone and analysis of forensic cases.

  2013cited by this paper
• Mass spectrometric investigation of chelerythrine and dihydrochelerythrine biotransformation patterns in human hepatocytes.

  2013cited by this paper
• Getting up to speed with the public health and regulatory challenges posed by new psychoactive substances in the information age.

  2013cited by this paper
• ‘Legal Highs’ – novel and emerging psychoactive drugs: a chemical overview for the toxicologist

  2012cited by this paper
• Drug abuse: newly-emerging drugs and trends.

  2012cited by this paper
• Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States

  2011cited by this paper
• Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography–linear ion trap–mass spectrometry (LC-MSn)

  2011cited by this paper
• Identification of benzo[c]phenanthridine metabolites in human hepatocytes by liquid chromatography with electrospray ion-trap and quadrupole time-of-flight mass spectrometry.

  2011cited by this paper
• Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.

  2010cited by this paper
• Metabolism of designer drugs of abuse: an updated review.

  2010cited by this paper

• Electrochemical Simulation of 25B-NBOMe Phase I Metabolism and Metabolite Profiling by HPLC-QTOF-MS

  2025cites this paper
• Nouveaux produits de synthèse

  2024cites this paper
• At the Origins of Tobacco-Smoking and Tea Consumption in a Virgin Population (Yakutia, 1650–1900 A.D.): Comparison of Pharmacological, Histological, Economic and Cultural Data

  2021cites this paper
• Impact of socio-economic traditions on current tobacco and tea addictions (Siberia 17th to 20th century).

  2021cites this paper
• 25CN-NBOMe Metabolites in Rat Urine, Human Liver Microsomes and C. elegans—Structure Determination and Synthesis of the Most Abundant Metabolites

  2021cites this paper
• N-éthylhexédrone : une longue descente !

  2021cites this paper
• E-liquides et cannabinoïdes de synthèse : focus sur l’analyse d’e-liquides de 2016 à 2020

  2020cites this paper
• Synthesis, determination of analytical characteristics and differentiation of positional isomers in the series of N-(2-methoxybenzyl)-2-(dimethoxyphenyl)ethanamine by means of chromatography-mass spectrometry.

  2020cites this paper
• Advances in Nanocarrier-Based Delivery of Therapeutic Peptides

  2020cites this paper
• Case report on two-cathinones abuse: MPHP and N-ethyl-4′methylnorpentedrone, with a fatal outcome

  2019cites this paper
• NBOMe compounds: An overview about analytical methodologies aiming their determination in biological matrices

  2019cites this paper
• In Vitro Metabolism of 25B-NBF, 2-(4-Bromo-2,5-Dimethoxyphenyl)-N-(2-Fluorobenzyl)ethanamine, in Human Hepatocytes Using Liquid Chromatography–Mass Spectrometry

  2019cites this paper
• Human biodistribution and radiation dosimetry of the 5-HT2A receptor agonist Cimbi-36 labeled with carbon-11 in two positions

  2019cites this paper
• Dark Classics in Chemical Neuroscience: NBOMes.

  2019cites this paper
• Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach.

  2018cites this paper
• Metabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry

  2018cites this paper
• Detection of the designer benzodiazepine flunitrazolam in urine and preliminary data on its metabolism.

  2018cites this paper
• Prevalence of new psychoactive substances and prescription drugs in the Belgian driving under the influence of drugs population.

  2018cites this paper
• Metabolism and Detectability of N-2-Methoxybenzyl- Substituted Phenethylamines in Urine and Human Liver Preparations by Hyphenated Low and High Resolution Mass Spectrometry

  2018cites this paper
• Fatality involving ocfentanil documented by identification of metabolites.

  2018cites this paper
• In vitro phase I metabolism of three phenethylamines 25D-NBOMe, 25E-NBOMe and 25N-NBOMe using microsomal and microbial models.

  2018cites this paper
• Synthesis and identification of metabolite biomarkers of 25C-NBOMe and 25I-NBOMe

  2017cites this paper
• The importance of small polar radiometabolites in molecular neuroimaging: A PET study with [11C]Cimbi-36 labeled in two positions

  2017cites this paper
• Metabolic Profile Determination of NBOMe Compounds Using Human Liver Microsomes and Comparison with Findings in Authentic Human Blood and Urine.

  2017cites this paper
• Characterization of hallucinogenic phenethylamines using high-resolution mass spectrometry for non-targeted screening purposes.

  2017cites this paper
• Metabolic fate and detectability of the new psychoactive substances 2‐(4‐bromo‐2,5‐dimethoxyphenyl)‐N‐[(2‐methoxyphenyl)methyl]ethanamine (25B‐NBOMe) and 2‐(4‐chloro‐2,5‐dimethoxyphenyl)‐N‐[(2‐methoxyphenyl)methyl]ethanamine (25C‐NBOMe) in human and rat urine by GC–MS, LC–MSn, and LC–HR–MS/MS approa

  2017cites this paper
• Identification of novel psychoactive substances 25B-NBOMe and 4-CMC in biological material using HPLC-Q-TOF-MS and their quantification in blood using UPLC-MS/MS in case of severe intoxications.

  2017cites this paper
• New psychoactive substances in a drugged driving population: Preliminary results

  2017cites this paper
• Retrospective identification of 25I-NBOMe metabolites in an intoxication case

  2017cites this paper
• Case reports: Four concomitant non-fatal intoxications with AB-FUBINACA and MDMA

  2017cites this paper
• Intoxication aiguë et consommation chronique de cathinones chez un polyconsommateur

  2017cites this paper
• Analyses capillaires d’un cas d’intoxication par la diphénidine et le 5-MeO-DALT fournissant des données sur les concentrations dans les cheveux de nombreux nouveaux produits de synthèse

  2017cites this paper
• In vitro Characterization of NPS Metabolites Produced by Human Liver Microsomes and the HepaRG Cell Line Using Liquid Chromatographyhigh Resolution Mass Spectrometry (LC-HRMS) Analysis: Application to Furanyl Fentanyl.

  2017cites this paper
• The comeback of Ecstasy: New designs and increased MDMA content

  2017cites this paper
• CHEMSEX, NPS & risk reduction management: Preliminary results of a pilot study

  2017cites this paper
• LSD instead of 25I-NBOMe: The revival of LSD? A case report

  2017cites this paper
• Chemsex, NPS et réduction des risques et des dommages : résultats préliminaires d’une étude pilote

  2017cites this paper
• Detection of the designer benzodiazepine metizolam in urine and preliminary data on its metabolism.

  2017cites this paper
• Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens.

  2017cites this paper
• LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques

  2017cites this paper
• New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics

  2016cites this paper
• Mass spectrometric properties of N-(2-methoxybenzyl)-2-(2,4,6-trimethoxyphenyl)ethanamine (2,4,6-TMPEA-NBOMe), a new representative of designer drugs of NBOMe series and derivatives thereof.

  2016cites this paper
• Next generation of novel psychoactive substances on the horizon - A complex problem to face.

  2015cites this paper